SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing significant volatility as investors digest the failure of the BlueBird 7 satellite to reach its intended orbit during a Blue Origin mission, though the community remains divided between those bracing for a sharp sell-off and those viewing the dip as a strategic buying opportunity. While the company confirmed insurance will cover the financial loss and reaffirmed its long-term deployment goals, market participants are heavily debating the reliability of launch providers, the impact of project delays, and the company's reliance on external partners for its upcoming constellation buildout.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is seeing significant market focus following the announcement of commercial yttrium metal production at its UK facility and a strategic investment in French processor Carester, bolstering the firm's non-China supply chain narrative. Investors are actively debating the impact of these developments against potential short-term dilution and the broader macro sensitivity of critical mineral stocks to government policy and trade tensions.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is currently driving significant community activity due to a low-float setup and speculative hype surrounding a presidential executive order aimed at fast-tracking psychedelic research for veteran mental health. Traders are closely monitoring for a potential short squeeze, though skeptical voices in the community warn of a 'buy-the-rumor' sell-off and potential volatility associated with micro-cap biotech momentum plays.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing heightened investor attention driven by strong bullish sentiment surrounding its lead asset, CAN-2409, and anticipation of upcoming data releases at the American Urological Association annual meeting. The community is actively discussing the potential for a significant squeeze on high short interest, while supporters emphasize the company's robust balance sheet and long-term value potential in the oncology space.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE is trending as its community doubles down on the revival of iconic internet culture by leveraging restored original comic-making tools. Investors are actively discussing the project's long-term conviction and persistent grassroots effort to cement its status as an original meme powerhouse.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is currently trending as retail investors ramp up activity ahead of the upcoming AACR conference, where new data for its SLS009 platform will be presented. The community is actively debating the potential for a short squeeze fueled by heavy call option positioning and large-scale short interest, while long-term supporters remain focused on the clinical potential of the GPS trial.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is rallying as investors react to reports of a partnership with Google to develop custom AI inference chips and memory-processing units. The community is actively debating whether this news represents a genuine re-rating of the stock's role in hyperscaler infrastructure or if recent price volatility is being driven by speculative momentum.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is seeing intense trading activity and community speculation driven by the anticipation of Phase 2b data for rezpegaldesleukin in alopecia areata, which remains a key binary event for the company. While the community is actively debating the potential for a clinical breakthrough, a lucrative partnership, or a legal settlement with Eli Lilly, traders are closely monitoring price volatility ahead of these major upcoming catalysts.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending following a massive 17 billion dollar acquisition of TopBuild, a move that retail investors and analysts view as a major consolidation play in the building materials industry. The community is heavily focused on how this acquisition, coupled with the leadership of Brad Jacobs, will drive long-term scaling and synergy, with many traders closely monitoring how this news impacts the company's valuation and potential future growth.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors react to its role as a key U.S.-based, vertically integrated rare earth producer amidst intensified geopolitical tensions and national security concerns. Community discussion is heavily focused on the company's long-term supply chain importance, its recent appearance on a major television segment, and the broader implications of U.S. government policy supporting domestic critical mineral independence.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IBRX

ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IBRX ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to...

<ul class="summary-bullets"><li>The founder said Trump “can make huge advances in transforming the health of Americans” following a White House push to accelerate psychedelic-therapy research.</li><li>He flagged evidence showing over 2x higher distant breast cancer recurrence risk in remission patients with lymphopenia, or reduced levels of key immune cells.</li><li>Further trials are planned to test whether post-COVID immune dysfunction associated with T-cell exhaustion can be reversed with Anktiva.</li></ul>Shares of ImmunityBio, Inc. (IBRX) drew fresh attention over the weekend after founder Patrick Soon-Shiong backed U.S. President Donald Trump’s psychedelic-policy push and flagged new data linking low immune-cell levels to a higher risk of breast-cancer recurrence, spotlighting Anktiva.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> snapped a three-week losing streak to end last week up 6%.<h2 class="st-heading-2">IBRX Founder Backs Trump Psychedelic Push</h2>Soon-Shiong responded over the weekend to a White House push to accelerate research into psychedelic therapies, including ibogaine,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2045586218315055363">saying on X</a> that the president “can make huge advances in transforming the health of Americans.”The remarks followed an executive order directing federal support toward state-level programs advancing psychedelic treatments for serious mental illness. The development, alongside a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrMakaryFDA/status/2045631018657370381">post on X</a> from FDA Commissioner Marty Makary that the agency is “moving proactively to advance potential therapies to address America’s mental health crisis,” a post Soon-Shiong also shared.Podcast host Joe Rogan said during the ceremony he had earlier texted Trump about ibogaine’s addiction-treatment potential and recalled the president replying, “Sounds great. Do you want FDA approval? Let’s do it.”<h2 class="st-heading-2">New Breast Cancer Risk Data</h2>In a separate weekend update, Soon-Shiong pointed to new findings linking lymphopenia, or reduced levels of key immune cells, to higher recurrence risk in patients with early-stage breast cancer in remission.“News will break tomorrow,” he&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2045665757665890677">said</a>. “Evidence of an INCREASE OF OVER 2 TIMES THE RISK of distant recurrence of breast cancer (in patients in remission) with lymphopenia (low TCells and low NK cells).” He added that absolute lymphocyte count “matters in patients in remission with early stage (1 to 3) breast cancer” and called it an “easy test to monitor lymphopenia and to address this increased risk.”Soon-Shiong later cited independent research presented by UCLA breast cancer oncologist Aditya Barda at the American Association for Cancer Research (AACR) meeting,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2045947022528934137">saying</a> that the data showed that “regardless of the stage of BREAST CANCER, that post Covid lymphopenia results in poorer prognosis, poorer response to treatment and even 2x higher recurrence when patients are in remission.”“The relationship of low NK and low T cells to breast cancer (and frankly all cancers) is so clear,” he added, calling the findings “very compelling.”<h2 class="st-heading-2">Trials Planned To Reverse Post-COVID Immune Dysfunction</h2>Additionally, Soon-Shiong responded to questions about how clinicians may address post-COVID lymphopenia, saying a patient is currently being treated under an FDA-authorized single-patient investigational new drug pathway.&nbsp;“This is a clinical study and not an approved indication, but we are finding what is known as T cell exhaustion,” he&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2045957658071683246">said</a>, adding that more clinical trials are planned to explore whether the condition can be reversed.The immune-cell findings are notable in the context of Anktiva, an IL-15-based immunotherapy that boosts natural killer cells and CD8 T cells, two immune cell types that help the body detect and destroy virus-infected and cancer cells.Soon-Shiong had earlier said clinicians at the University of California, Los Angeles and the Mount Sinai Health System were observing links between lymphopenia after COVID and a rising incidence of metastatic disease and cancer recurrence in patients who had previously been in remission. He added that those concerns were “being validated” by emerging data presented at the AACR summit.ImmunityBio is already evaluating Anktiva in a Phase 2 study in patients with persistent post-COVID symptoms to test whether restoring immune-cell balance may correct underlying immune dysfunction.<h2 class="st-heading-2">Founder Defends Anktiva As Policy Momentum Builds</h2>The latest updates follow recent regulatory scrutiny of Anktiva after the FDA issued a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/immunitybio-founder-fda-warning-letter-anktiva-ad-never-aired/cZJpYnYRIHR">warning letter</a> citing promotional language that referenced uses beyond the therapy’s approved indication. Soon-Shiong pushed back publicly, saying a television advertisement cited by regulators “never aired at all.”Anktiva, approved in 2024 with standard BCG for certain bladder-cancer patients who no longer respond to standard therapy, is now being studied across multiple tumor types and severe inflammatory conditions. The therapy has also expanded internationally after conditional marketing authorization from the European Commission across the European Union, plus Iceland, Liechtenstein and Norway.Soon-Shiong has previously said&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-rally-not-over-yet-chairman-says-trump-diplomacy-led-to-amazing-results-for-cancer-drug/cZRZDoZR4Dx">that talks with Trump</a> and Saudi Crown Prince Mohammed bin Salman helped accelerate regulatory progress and the global rollout of the company’s Bioshield platform, including steps supporting lung cancer approvals and regional deployment across the Middle East and North Africa.<h2 class="st-heading-2">How Do Retail Traders Feel About IBRX?</h2>On Stocktwits, retail sentiment for IBRX has improved to ‘neutral’ from ‘bearish’ levels over the past week amid a 70% jump in message volumes during the same period.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_30d9175bac.webp" alt="ibrx ss.png" width="969" height="142"><figcaption>IBRX sentiment and message volume as of April 19 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Hotresearchsgoldenage/message/650731488">said</a>, “sold a good bit Friday at 7.84 with the intention to buy my khc stock back but now I’m buying a ton of Ibrx tommorow. Don’t be a panican! A mountain of money is waiting to get in here.”<stembedurl>https://stocktwits.com/Hotresearchsgoldenage/message/650731488</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Quantum_Long/message/650729851">expressed</a> optimism for Anktiva’s broader approval in additional approvals saying, “zero doubt this is coming before the midterms.&nbsp; Trump will have the heyday of curing cancer during his term.”<stembedurl>https://stocktwits.com/Quantum_Long/message/650729851</stembedurl>IBRX stock has jumped 212% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/asts-stock-bluebird-7-orbit-failure-satellite-exit-network-buildout/cZB5uQiRIy9">ASTS Stock Slumps Overnight: BlueBird-7 Orbit Failure Forces Satellite Exit From Network Buildout</a>

Dr. Patrick Soon-Shiong arrives at Trump National Golf Club Bedminster in Bedminster Township, N.J. on Saturday, Nov. 19, 2016. (Photo by Jabin Botsford/The Washington Post via Getty Images)

IBRX Founder Backs Trump’s Psychedelic Push In ‘Transforming’ Health Policy — Flags New Anktiva Breast Cancer Risk Data

The updates follow a recent FDA warning letter on promotional claims tied to Anktiva, which the founder publicly disputed.

Equity

ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX

ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff...

IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman

IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued...

ImmunityBio (NASDAQ:IBRX) Trading Down 5.3% - Time to Sell?

ImmunityBio (NASDAQ:IBRX) Trading Down 5.3% - Should You Sell...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX INVESTOR ALERT: Pomerantz Law Firm...

IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi...

INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces INVESTOR DEADLINE: ImmunityBio...

IBRX Lawsuit Alleges Chairman Allegedly Concealed Drug Limitation Risks - ImmunityBio Investors Face Losses Following Chairman Allegedly Concealed Drug Limitation Risks: SueWallSt

IBRX Lawsuit Alleges Chairman Allegedly Concealed Drug Limitation Risks - ImmunityBio Investors Face Losses Following Chairman Allegedly Concealed Drug Limitation Risks: SueWallSt IBRX Lawsuit...

Robbins LLP Urges IBRX Stockholders Who Lost Money Investing in ImmunityBio, Inc. to Contact the Firm for Information About Leading the Class Action

Robbins LLP Urges IBRX Stockholders Who Lost Money Investing in ImmunityBio, Inc. to Contact the Firm for Information About Leading the Class Action Robbins LLP Urges IBRX Stockholders Who Lost Money...

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Bullish continuation

Sideways chop

Fade lower

Full reversal

The market rebounded fast this week — what’s your call for next week?

Stocktwits

Stocktwits Polls

Investors are tracking the CEO’s international travel, particularly to Japan, as a strategic move to bypass regulatory hurdles and establish global manufacturing hubs.

The community is vocally criticizing the FDA's slow review process, contrasting it with recent political support for faster, data-driven treatment approvals.

Traders are closely watching for imminent clinical and regulatory milestones, anticipating a significant revaluation if pending partnerships are realized.

Investors are actively calling out negative media and institutional short activity, citing fundamental advancements to counter the persistent bear thesis.

Current Price	$7.70
Prev Close	$7.25
Open	$7.30
Dividend Yield	0.00%
50-Day Moving Average	$7.97
Beta	1.92
Avg. Volume	27.67M
PE Ratio	-19.75

52-Week High	$12.43
52-Week Low	$1.83
Market Capitalization	$7.92B
EPS (Annual)	-$0.382
Price to Book	-15.57
Revenue Per Employee	$163,947.90

IBRX
ImmunityBio Inc

Feed

News

Sentiment

Fundamentals

Info

Latest IBRX News

IBRXImmunityBio Inc